Ex-Janssen India chief and BSV CEO Sanjiv Navangul shares with Scrip glimpses of his life and professional journey including chasing the IAS dream early on, the heady days at Hoechst with a stint in Moscow, challenges around Sirturo’s debut and unprecedented preps that fueled Januvia’s big run during his innings at MSD.
Industry veteran Sanjiv Navangul is known for his out-of-the box thinking and has steered several high-profile launches during his leadership stints at big pharma in India.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
The drugmaker said in its first quarter earnings that it did not foresee negative effects on potential approval and launch of lenacapavir for PrEP later this year.
On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
